title: A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells.
abstract: Proline/arginine-rich end leucine-rich repeat protein (PRELP) belongs to the small leucine-rich proteoglycan (SLRP) family, normally expressed in extracellular matrix of collagen-rich tissues. We have previously reported on another SLRP, fibromodulin (FMOD) in patients with chronic lymphocytic leukemia (CLL). PRELP is structurally similar to FMOD with adjacent localization on chromosome 1 (1q32.1). As cluster-upregulation of genes may occur in malignancies, the aim of our study was to analyze PRELP expression in CLL. PRELP was expressed (RT-PCR) in all CLL patients (30/30), as well as in some patients with mantle cell lymphoma (3/5), but not in healthy donor leukocytes (0/20) or tumor samples from other hematological malignancies (0/35). PRELP was also detected in CLL cell-lines (4/4) but not in cell-lines from other hematological tumors (0/9). PRELP protein was detected in all CLL samples but not in normal leukocytes. Deglycosylation experiments revealed a CLL-unique 38 kDa core protein, with an intact signal peptide. This 38 kDa protein was, in contrast to the normal 55 kDa size, not detected in serum which, in combination with the uncleaved signal peptide, suggests cellular retention. The unique expression of a 38 kDa PRELP in CLL cells may suggest involvement in the pathobiology of CLL and merits further studies.
authors.affiliation: Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. eva.mikaelsson@ki.se
authors.forename: Eva
authors.initials: E
authors.lastname: Mikaelsson
authors.forename: Anders
authors.initials: A
authors.lastname: Österborg
authors.forename: Mahmood
authors.initials: M
authors.lastname: Jeddi-Tehrani
authors.forename: Parviz
authors.initials: P
authors.lastname: Kokhaei
authors.forename: Mahyar
authors.initials: M
authors.lastname: Ostadkarampour
authors.forename: Reza
authors.initials: R
authors.lastname: Hadavi
authors.forename: Mehran
authors.initials: M
authors.lastname: Gholamin
authors.forename: Mehdi
authors.initials: M
authors.lastname: Akhondi
authors.forename: Fazel
authors.initials: F
authors.lastname: Shokri
authors.forename: Hodjattallah
authors.initials: H
authors.lastname: Rabbani
authors.forename: Håkan
authors.initials: H
authors.lastname: Mellstedt
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000918:Antibody Specificity / Q000276:immunology; D015153:Blotting, Western; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D016326:Extracellular Matrix Proteins / Q000097:blood / Q000235:genetics* / Q000276:immunology; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006023:Glycoproteins / Q000097:blood / Q000235:genetics* / Q000276:immunology; D006031:Glycosylation; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000235:genetics* / Q000276:immunology / Q000473:pathology*; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D020033:Protein Isoforms / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D011994:Recombinant Proteins / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; C096382:PRELP protein, human; D020033:Protein Isoforms; D011994:Recombinant Proteins